Company profile
Bioethics, Ltd.
OTC: BOTH · Financial Services · Shell Companies
#878 of 1,012 Financial Services companies by revenue
EA Score
——FH —DQ 48GM —SS 26
v0.1 · 25/100 weight · pillars only
↑ disclosure history, listing tenure · ↓ workforce scale, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$177.0k
Employees
1
as of 2026-08-29
Market cap
$18.4k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$177.0k-$177.0k2024
Operating income-$122.8k-$122.8k2024
Total assets$14.7k$14.7k2024
Liabilities$945.9k$945.9k2024
Equity-$931.2k-$931.2k2024
Revenue trend
FY2014 – FY2024 · USD
FY14
FY19
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bioethics, Ltd.’s revenue?
Bioethics, Ltd. booked $0 in FY2024 revenue — among the slowest-growing Financial Services companies we track, at a -Infinity% net margin.
Peers · Financial Services
Myrexis, Inc.——Rainbow International Corp.——Trimol Group, Inc.——Sky440, Inc.——Crown Baus Capital Corp.——Immage Biotherapeutics Corp.——Key facts
CEOMark A. Scharmann
SectorFinancial Services
IndustryShell Companies
HeadquartersOgden, UT
ExchangeOTC: BOTH
Employees1
IPO date2002-06-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.